Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

Sponsor
William Beaumont Hospitals (Other)
Overall Status
Recruiting
CT.gov ID
NCT02870738
Collaborator
Baylor College of Medicine (Other)
128
1
2
87.4
1.5

Study Details

Study Description

Brief Summary

Women with interstitial cystitis/bladder pain syndrome (IC/BPS) have debilitating urinary frequency and urgency, and chronic pelvic or bladder pain perceived to be related to the bladder. Although many clinicians think that IC/BPS symptoms result from a bladder problem, tight pelvic floor muscles can cause similar symptoms and might be responsible for ICBPS symptoms instead of the bladder. Inadequate assessment of the problem leads to delays in treatment and often years of suffering. This clinical trial will test a bladder directed therapy (bladder instillations) compared to a course of pelvic floor physical therapy (PFPT) to assess the role of the pelvic floor as a major contributor to pelvic pain and voiding dysfunction in adult women with non-ulcerative IC/BPS. Early assessment of the pelvic floor muscles in patients with IC/BPS symptoms may prevent common delays in proper diagnosis and allow for early, more effective treatment.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pelvic Floor Physical Therapy
  • Drug: Bladder Instillations
Phase 2

Detailed Description

This will be a prospective randomized trial of pelvic floor therapy vs. bladder directed therapy. The study target population consists of females, aged 18 to 85 years of age with a clinical diagnosis of IC/BPS and symptoms of chronic urinary frequency, pelvic pain/discomfort, and/or urinary urgency. The approximate number of subjects that will be enrolled in the study is 128, 64 women in each treatment group. Women who satisfy all of the eligibility criteria will be enrolled in the study and randomized to receive bladder treatments (instillation of medications into the bladder) or pelvic floor physical therapy.

Outcome measures will include validated questionnaires, voiding diaries, and Global Response Assessment (GRA). The investigators also will evaluate changes in pelvic floor muscle tone and discomfort pre and post treatment, and their relationship to symptom changes. Finally, the investigators will utilize their well-established urine and serum biomarkers evaluations pre and post treatment to determine if they correlate with symptom change.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
128 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome
Actual Study Start Date :
Apr 21, 2017
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Pelvic Floor Physical Therapy

One hour of pelvic floor physical therapy twice weekly for 8 weeks

Procedure: Pelvic Floor Physical Therapy
Internal and/or external myofascial release of the pelvic floor muscles
Other Names:
  • Myofascial release
  • Active Comparator: Bladder Instillations

    Bladder instillation of lidocaine, kenalog, heparin sulphate, and bicarbonate twice weekly for 8 weeks

    Drug: Bladder Instillations
    A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
    Other Names:
  • xylocaine, triamcinolone
  • Outcome Measures

    Primary Outcome Measures

    1. Markedly/Moderately Improved on Global Response Assessments [Week 9 (one week after last treatment)]

      Proportion of patients in each treatment arm that report Marked or Moderate improvement in symptoms on Global Response Assessments at Week 9 (one week after last treatment)

    Secondary Outcome Measures

    1. Change in symptoms [Week 9 (one week after last treatment)]

      Change in pelvic floor examination findings and symptoms as measured by questionnaires at Week 9 (one week after last treatment)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Female

    • Age 18 to 85 years

    • History of patient self-reported of IC/BPS symptoms for at least 6 months.

    • Using an approved method of birth control, or surgically sterile, or of non-child bearing age with no menstrual period for the past 12 months

    • Must be willing to not start any new medication known to affect bladder or muscle function, and to ideally remain on a stable dose of all other medications through the secondary endpoint.

    Exclusion Criteria:
    • Active urethral or ureteral calculi, urethral diverticulum, history of pelvic radiation therapy, tuberculous cystitis, bladder cancer, carcinoma in situ (bladder), urethral cancer

    • Hunner's lesions found on screening cystoscopy

    • Prior investigational or therapeutic bladder instillations for IC/BPS symptoms within the past 3 months

    • Lactation, pregnancy, or refusal of medically approved/reliable birth control in women of child-bearing potential.

    • Pain, frequency, and/or urgency symptoms only present during menses

    • Clinically confirmed urinary tract infection at time of screening

    • Participant unable to tolerate insertion of one or two vaginal examining fingers (e.g. Vulvar allodynia)

    • Participant had prior course of physical therapy (PT) that included internal (vaginal and/or rectal) manual therapy with connective tissue manipulation by physical therapist for the same symptoms within the past 3 months (prior treatment by therapist with biofeedback, electrical stimulation, or pelvic floor exercises is not exclusionary)

    • Participant in the opinion of the investigator has a relevant neurologic disorder that affects bladder and/or neuromuscular function

    • Participant has/reports any severe, debilitating or urgent concurrent, medical condition

    • Participant has a potentially significant pelvic pathology or abnormality on examination or prior imaging, including prolapse beyond the hymenal ring, pelvic mass, etc., that in the investigators' judgment, could cause or contribute to the clinical symptoms, or require treatment

    • Any other condition which, in the investigator's judgment, may increase risk to subject's welfare

    • Participation in an investigational trial that uses a study treatment less than 6 months from the date of the screening visit

    Note: For the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 William Beaumont Hospital Royal Oak Michigan United States 48073

    Sponsors and Collaborators

    • William Beaumont Hospitals
    • Baylor College of Medicine

    Investigators

    • Principal Investigator: Kenneth M Peters, MD, Beaumont Hospital-Royal Oak

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kenneth M Peters, MD, Professor and Chairman of Urology, William Beaumont Hospitals
    ClinicalTrials.gov Identifier:
    NCT02870738
    Other Study ID Numbers:
    • 2016-253
    First Posted:
    Aug 17, 2016
    Last Update Posted:
    May 9, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 9, 2022